Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5892_Библиотеки_им_академика_М_И_Перельмана
.pdf
268
https://t.me/med1917
hydrolysis of 25 under the condition of NaOH/n-heptane will afford the desired ciprofol
(1) in 90% yield with over 99% de. The overall yield of this endgame route was 12–14%.
Chemistry and Pharmacology of Drug Discovery
7. Summary
Dating back to the discovery of propofol (2) in 1977, the patent of propofol (2) has expired
for many years. When considering something in retrospect as medicine chemists, we must
think about why ciprofol (1) is still discovered and developed? Firstly, drug is developed
to meet the clinical needs of patients as the highest priority. Secondly, patentability is a
magic weapon for drugs. Ciprofol (1) is currently approved to indications including
sedation in gastrointestinal endoscopy, followed by anesthesia during the
surgical/procedure of nontracheal intubation, induction and maintenance of general
anesthesia, and sedation during intensive care by China in 2020. Numerous clinical trials
investigating ciprofol (1) have consistently demonstrated its benefits,
tolerance, higher sedation satisfaction score, and reduced occurrence of adverse reactions
(respiratory depression and decrease blood pressure). Particularly noteworthy is its
remarkable effectiveness in significantly decreasing the frequency of injection-related pain.
There is a scarcity of long-term medication experience and comprehensive clinical data
validating its efficacy in broader clinical scenarios due to a short period on the market. Still,
a lack of clinical research data about ciprofol (1) in patients under 18 years old and pregnant
and lactating women will not be recommended for their treatments. The familiarity and
proficiency of anesthesiologists with propofol (2) make it challenging to envision a fullscale transition to ciprofol (1), as well as medicinal cost for patients. Compared to propofol
(2), the complexity of chemical process is still more challenging due to a chiral center of
one side chain. With further investigation and understanding, ciprofol (1) holds the
potential to offer additional benefits to patients, ultimately enhancing the field of anesthesia.
2
including enhanced
References
1. Sneyd, J. R. Thiopental to desflurane-an anaesthetic journey. Where are
2. Lu M; Liu J; Wu X.; Zhang Z. Ciprofol: a novel alternative to propofol
3. Sneyd J. R. Excitatory events associated with Propofol anaesthesia: a
4. Thompson, K. A.; Goodale, D. B. The recent development of Propofol
5. Glen J.; James R. 2,6-Diisopropylphenol as an anaesthetic agent.
we going next?
in clinical intravenous anesthesia? Biomed Res. Int. 2023, 2023, 1–12.
review. J. Royal Soc. Med. 1992, 85, 288–291.
(DIPRIVAN
US4056635A 1997.
Br. J. Anaesth. 2017, 119, 44–52.
®
). Intensive Care Med. 2000, 26, S400.
269
https://t.me/med1917
6. Andropoulos, D. B.; Greene, M. F. Anesthesia and developing brains –
7. Creeley, C.; Dikranian, K.; Dissen, G.; Martin, L.; Olney, J.; Brambrink,
8. Jenkins T. E. Stereoisomers propofol therapeutic compounds.
9. Boules, R.; Szkiladz, A.; Nogid, A. Fospropofol disodium (lusedra)
10. Sneyd, J. R.; Rigby-Jones, A. E. New drugs and technologies,
11. Qin, L.; Ren, L.; Wan, S.; Liu, G.; Luo, X.; Liu, Z.; Li, F.;, Yu, Y.; Liu,
12. Liu, Y.; Yu, X.; Zhu, D.; Zeng, J.; Lin, Q.; Zang, B.; Chen, C.; Liu, N.;
13. Qin, K.; Qin, W.; Ming, S.; Ma, X.; Du, X. Effect of ciprofol on
14. Teng, Y.; Ou, M.; Wang, X.; Zhang, W.; Liu, X.; Liang, Y.; Li, K.;
15. Li, J.; Wang, X.; Liu, J.; Wang, X.; Li, X.; Wang, Y.; Ouyang, W.; Li,
16. Wu, B.; Zhu, W.; Wang, Q.; Ren, C.; Wang, L.; Xie, G. Efficacy and
Chapter 12. Ciprofol (Cipepofol)
implications of the FDA warning. N. Engl. J. Med. 2017, 376, 905–907.
A. Propofol-induced apoptosis of neurones and oligodendrocytes in fetal
and neonatal rhesus macaque brain.
US8242315B2 (2008).
injection for anesthesia-care sedation: a clinical review. Pharm. Ther.,
2012, 37, 395.
intravenous anaesthesia is on the move (again). Br. J. Anaesth. 2010,
105, 246–254.
J.; Wei, Y. Design, synthesis, and evaluation of novel 2, 6-disubstituted
phenol derivatives as general anesthetics. J. Med. Chem. 2017, 60, 3606–
3617.
Liu, X.; Gao, W.; Guan, X. Safety and efficacy of ciprofol vs. propofol
for sedation in intensive care unit patients with mechanical ventilation: a
multi-center, open label, randomized, phase 2 trial. Chin. Med. J. 2022,
135, 1043–1051.
induction and maintenance of general anesthesia in patients undergoing
kidney transplantation. Eur. Rev. Med. Pharmacol. Sci. 2022, 26, 5063–
5071.
Wang, Y.; Ouyang, W.; Weng, H.; Li, J. Efficacy and safety of ciprofol
for the sedation/anesthesia in patients undergoing colonoscopy: phase IIa
and IIb multi-center clinical trials, Eur. J. Pharm. Sci. 2021, 164,
105904.
J.; Yao, S.; Zhu, Z.; Guo, Q. Comparison of ciprofol (HSK3486) versus
propofol for the induction of deep sedation during gastroscopy and
colonoscopy procedures: a multi-centre, non-inferiority, randomized,
controlled phase 3 clinical trial. Basic Clin. Physiol. Pharmacol. 2022,
131, 138–148.
safety of ciprofol-remifentanil versus propofol-remifentanil during
fiberoptic bronchoscopy: a prospective, randomized, double-blind, non-
Br. J. Anaesth. 2013, 110, 29–38.
270
https://t.me/med1917
17. Luo, Z.; Tu, H.; Zhang, X.; Wang, X.; Ouyang, W.; Wei, X.; Zou, X.;
18. Zeng, Y.; Wang, D.; Lin, Z.; Liu, J.; Wei, X. C.; Deng, J.; Liu, Y. F.;
19. Wang, X.; Liu, J.; Zuo, Y.; Zhu, Q. M.; Wei, X. C.; Zou, X. H.; Luo, A.
20. Liu, Y.; Chen, C.; Liu, N.; Tong, L.; Nie, Y.; Wu, J.; Liu, X.; Gao, W.;
21. Li, X.; Yang, D.; Li, Q.; Wang, H.; Wang, M.; Yan, P.; Wu, N.; Li, F.;
22. Teng, Y.; Ou, M.; Wang, X.; Zhang, W. S.; Liu, X.; Liang, Y.; Zuo, Y.
23. Hu, C.; Ou, X.; Teng, Y.; Shu, S.; Wang, Y.; Zhu, X.; Kang, Y.; Miao,
24. Liang, P.; Dai, M.; Wang, X.; Wang, D.; Yang, M.; Lin, X.; Zou, X.;
Chemistry and Pharmacology of Drug Discovery
inferiority trial. Front. Pharmacol. 2022, 13, 1091579.
Zhu, Z.; Li, Y.; Shangguan, W.; Wu, H. Efficacy and safety of HSK3486
for anesthesia/sedation in patients undergoing fiberoptic bronchoscopy:
a multicenter, double-blind, propofol-controlled, randomized, phase 3
study. CNS Drugs 2022, 36, 301–313.
Ma, E. L.; Yang, M. C.; Zheng, H.; Yu, X. D. Efficacy and safety of
HSK3486 for the induction and maintenance of general anesthesia in
elective surgical patients: a multicenter, randomized, open-label,
propofol-controlled phase 2 clinical trial. Eur. Rev. Med. Pharmacol. Sci.
2022, 26, 1114–1124.
L.; Zhang, F. X.; Li, Y. L.; Zheng, H.; Li, H. Effects of ciprofol for the
induction of general anesthesia in patients scheduled for elective surgery
compared to propofol: a phase 3, multicenter, randomized, double-blind,
comparative study. Eur. Rev. Med. Pharmacol. Sci. 2022, 26, 1607–
1617.
Tang, L.; Guan, X. Efficacy and safety of ciprofol sedation in ICU
patients with mechanical ventilation: a clinical trial study protocol. Adv.
Ther. 2021, 38, 5412–5423.
Ma, S.; Ding, Y.; Liu, J. Safety, pharmacokinetics, and
pharmacodynamics of a single bolus of the γ-aminobutyric acid (GABA)
receptor potentiator HSK3486 in healthy Chinese elderly and nonelderly. Front. Pharmacol. 2021, 12, 735700.
X.; Zhu, T.; Liu, B.; Liu, J. Pharmacokinetic and pharmacodynamic
properties of ciprofol emulsion in Chinese subjects: a single center,
open-label, single-arm dose-escalation phase 1 study. Am. J. Transl. Res.
2021, 13, 13791–13802.
J. Sedation effects produced by a ciprofol initial infusion or bolus dose
followed by continuous maintenance infusion in healthy subjects: a
phase 1 trial. Adv. Ther. 2021, 38, 5484–5500.
Jiang, K.; Li, Y.; Wang, L.; Shangguan, W. Efficacy and safety of
ciprofol vs. propofol for the induction and maintenance of general
anaesthesia: a multicentre, single-blind, randomised, parallel-group,
271
https://t.me/med1917
25. Chen, B.; Yin, X.; Jiang, L.; Liu, J. H.; Shi, Y. Y.; Yuan, B. Y. The
26. Long, Y.; Feng, C.; Ding, Y.; Feng, X. M.; Liu, H.; Ji, F. H.; Peng, K.
27. Chen, X.; Guo, P.; Yang, L.; Liu, Z.; Yu, D. Comparison and clinical
28. Hu, Y.; Li, X.; Liu, J..; Chen, H.; Zheng, W.; Zhang, H.; Wu, M.; Li,
29. Zhu, Q.; Luo, Z.; Wang, X.; Wang, D.; Li, J.; Wei, X.; Tang, J.; Yao,
30. Zhong, J.; Zhang, J.; Fan, Y.; Zhu, M.; Zhao, X.; Zuo, Z.; Zhou, X.;
31. Yu, L.; Bischof, E.; Lu, H. Anesthesia with ciprofol in cardiac surgery
32. Man, Y.; Xiao, H.; Zhu, T.; Ji, F. Study on the effectiveness and safety
33. Silverman, R. B. Design and mechanism of GABA aminotransferase
34. Trapani, G.; Altomare, C.; Sanna, E.; Biggio, G.; Liso, G. Propofol in
Chapter 12. Ciprofol (Cipepofol)
phase 3 clinical trial. Eur. J. Anaesthesiol. 2023, 40, 399–406.
efficacy and safety of ciprofol use for the induction of general anesthesia
in patients undergoing gynecological surgery: a prospective randomized
controlled study. BMC Anaesthesiol. 2022, 22, 245.
Esketamine as an adjuvant to ciprofol or propofol sedation for same-day
bidirectional endoscopy: protocol for a randomized, double-blind,
controlled trial with factorial design. Front. Pharmacol. 2022, 13,
821691.
value of ciprofol and propofol in intraoperative adverse reactions,
operation, resuscitation, and satisfaction of patients under painless
gastroenteroscopy anesthesia. Contrast Media Mol. Imaging, 2022,
2022, 9541060.
C.; Zhu, X.; Lou, J.; Yan, P. Safety, pharmacokinetics and
pharmacodynamics
potentiator, HSK3486, in Chinese patients with hepatic impairment.
Ann. Med., 2022, 54, 2757–2768.
S.; Ouyang, W.; Zhang, W.; Zuo, Y. Efficacy and safety of ciprofol
versus propofol for the induction of anesthesia in adult patients: a
multicenter phase 2a clinical trial. Int. J. Clin. Pharm. 2023, 45, 473.
Miao, C. Efficacy and safety of ciprofol for procedural sedation and
anesthesia in non-operating room settings. J. Clin. Anesth. 2023, 85,
111047.
with cardiopulmonary bypass: a case report. World J. Clin. Cases 2023,
11, 157–163.
of ciprofol in anesthesia in gynecological day surgery: a randomized
double-blind controlled study. BMC Anesthesiol. 2023, 23, 92.
inactivators. Treatments for epilepsies and addictions. Chem. Rev. 2018,
118, 4037–4070.
anesthesia. Mechanism of action, structure-activity relationships, and
drug delivery. Curr. Med. Chem. 2000, 7, 249-271.
of a novel γ-aminobutyric acid (GABA) receptor
272
https://t.me/med1917
35. Liao, J.; Li, M.; Huang, C.; Yu, Y.; Chen, Y.; Gan, J.; Xiao, J.; Xiang,
36. Nury, H.; Renterghem, C.; Weng, Y.; Tran, A.; Baaden, M.; Dufresne,
37. Koichi, Y.; Bu, W.; Xi, J.; Shimaoka, M.; Eckenhoff, R. Propofol shares
38. Orser, B.; Wang, L.; Pennefather, P.; MacDonald, J. Propofol modulates
39. a) Concas, A.; Santoro, G.; Mascia, M. P.; Serra, M.; Sanna, E.; Biggio,
40. Collins, G. G. Effects of the anaesthetic 2,6-diisopropylphenol on
41. Woll, K.; Weiser, B.; Liang, Q.; Meng, T.; McKinstry-Wu, A.; Pinch,
42. Qiu, L.; Lin, J.; Liu, Q.; Wang, S.; Lv, G.; Li, K.; Shi, H.; Huang, Z.;
43. James, R.; Glen, J. B. Synthesis, biological evaluation, and preliminary
44. Trapani, G.; Latrofa, A.; Franco, M.; Altomare, C.; Sanna, E.; Usala,
Chemistry and Pharmacology of Drug Discovery
G.; Ding, X.; Jiang, R.; Li, P. Pharmacodynamics and pharmacokinetics
of HSK3486, a novel 2, 6-disubstituted phenol derivative as a general
anesthetic, Front. Pharmacol. 2022, 13, 830791.
V.; Changeux, J. P.; Sonner, J. M.; Delarue, M.; Corringer, P. J. X-ray
structures of general anaesthetics bound to a pentameric ligand-gated ion
channel. Nature 2011, 469, 428–431.
the binding site with isoflurane and sevoflurane on leukocyte functionassociated antigen-1. Anaesth. Analg. 2013, 117, 803–811.
activation and desensitization of GABAA receptors in cultured murine
hippocampal neurons. J. Neurosci. 1994, 14, 7747–7760.
G. The general anesthetic propofol enhances the function of γ-
aminobutyric acid-coupled chloride channel in the rat cerebral cortex. J.
Neurochem., 1990, 55, 2135; b) Concas, A.; Santoro, G.; Serra, M.;
, E.; Biggio, G. Neurochemical action of the general anaesthetic
Sanna
propofol on the chloride ion channel coupled with GABAA receptors.
Brain Res. 1991, 542, 225.
synaptic transmission in the rat olfactory cortex slice. Br. J. Pharmacol.
1988, 95, 939.
B.; Dailey, W. P.; Gao, W. D.; Covarrubias, M.; Eckenhoff, R. G. Role
for the propofol hydroxyl in anesthetic protein target molecular
recognition. ACS Chem. Neurosci. 2015, 6, 927–935.
Bertaccini, E. J. The role of the hydroxyl group in propofol–protein
target recognition: insights from ONIOM studies. J. Phys. Chem. B 2017,
121, 5883–5896.
structure-activity considerations of a series of alkylphenols as
intravenous anesthetic agents. J. Med. Chem. 1980, 23, 1350–1357.
M.; Biggio, G.; Liso, G. Propofol analogues. Synthesis, relationships
between structure and affinity at GABAA receptor in rat brain, and
differential electrophysiological profile at recombinant human GABAA
receptors. J. Med. Chem. 1998, 41, 1846–1854.
273
https://t.me/med1917
Chapter 12. Ciprofol (Cipepofol)
45. Lingamaneni, R.; Krasowski, M.; Jenkins, A.; Truong, T.; Giunta, A. L.;
Blackbeer, J.; MacIver, M. B.; Harrison, N. L.; Hemmings, H. C.
Anesthetic properties of 4-iodopropofol: implications for mechanisms of
anesthesia. J. Am. Soc. Anesth.
2001, 94, 1050-1057.
46. a) Hill-Venning, C.; Peters, J. A.; Callachan, H.; Lambert, J. J.;
Gemmell, D. K.; Anderson, A.; Byford, A.; Hamilton, N.; Hill, D. R.;
Marshall, R. J.; Campbell, A. C. The anesthetic action and modulation
of GABAA receptor activity by the novel water-soluble aminosteroid
Org 20599. Neuropharmacology 1996, 35, 1209–1222; b) Lingamaneni
R.; Krasowski, M.; Jenkins, A.; Truong, T.; Giunta, A. L.; Blackbeer,
J.; MacIver, M. B.; Harrison, N. L.; Hemmings, H. C. Anesthetic
properties of 4-iodopropofol: implications for mechanisms of anesthesia.
J. Am. Soc. Anesth. 2001, 94, 1050–1057.
47. Bian, Y.; Zhang, H.; Ma, S.; Jiao, Y.; Yan, P.; Liu, X.; Ma, S.; Xiong,
Y.; Gu, Z.; Yu, Z.; Huang, C. Mass balance, pharmacokinetics and
pharmacodynamics of intravenous HSK3486, a novel anaesthetic,
administered to healthy subjects. Br. J. Clin. Pharmacol. 2021, 87, 93–
105.
48. a) Simons, P. J.; Cockshott, I. D.; Douglas, E. J.; Gordon, E. A.,
Hopkins, K.; Rowland, M. Disposition in male volunteers of a
14
subanaesthetic intravenous dose of an oil in water emulsion of
Cpropofol. Xenobiotica 1988, 18, 429–440; b) Sahinovic, M.; Struys, M.;
Absalom, A. Clinical pharmacokinetics and pharmacodynamics of
propofol. Clin. Pharmacokinet. 2018, 57, 1539–1558.
49. Hu, C.; Ou, X.; Teng, Y.; Shu, S.; Wang, Y.; Zhu, X.; Kang, Y.; Miao,
J. Sedation effects produced by a ciprofol initial infusion or bolus dose
followed by continuous maintenance infusion in healthy subjects: a
phase 1 trial. Adv. Ther. 2021, 38, 5484–5500.
50. Voss, L. J.; Sleigh, J. W.; Barnard, J. P.; Kirsch, H. E. The howling
cortex: seizures and general anesthetic drugs. Anesth. Analg. 2008, 107,
1689–1703.
51. Chen, B.; Yin, X.; Jiang, L.; Liu, J.; Shi, Y. Y.; Yuan, B. Y. The efficacy
and safety of ciprofol use for the induction of general anesthesia in
patients undergoing gynecological surgery: a prospective randomized
controlled study. BMC Anesthesiol. 2022, 22, 1–7.
52. Yang, D.; Hu, Y.; Ruan, Z.; Jiang, B.; Wang, H.; Xu, Y.; Hu, M.; Yan,
M.; Lou, H. Drug–drug interaction of ciprofol injectable emulsion with
mefenamic acid capsules in healthy subjects. Br. J. Clin. Pharmacol.
2023, 89,
3165–3174.
53. Zhang, X.; Yu, S.; Liu, Z.; Long, Y.; Zhao, J.; Xu, W.; Zhang, H.;
,
274
https://t.me/med1917
54. Jenkins, T. E. Analogs of propofol, preparation thereof and use as
Chemistry and Pharmacology of Drug Discovery
Zhang, H. Development of a kilogram-scale route for clinical sample
production of the intravenous anesthetic cipepofol. Org. Process Res.
Dev. 2022, 26, 1054–1062.
anesthetics, WO2009140275A1 (2009).
https://t.me/med1917
13
________________________________________________________________________
Rimegepant (Nurtec ODT): A CGRP
Receptor Antagonist as a Treatment of
Episodic Migraine
Yuqi Lavender Zha and
Guanglin Luo
FDA’s 2020 approval rimegepant (Nurtec ODT, 1), a calcitonin gene-related peptide
(CGRP) receptor antagonist as a treatment of episodic migraine in adults, is good news
for millions of patients suffering from episodic migraine.
Rimegepant (1) is the second CGRP small-molecule antagonist on the market.
The other two small-molecule CGRP receptor antagonists, ubrogepant (Ubrelvy, 2) and
atogepant (Qulipta, 3) were approved in 2019 and 2021, respectively.
Chemistry and Pharmacology of Drug Discovery, First Edition. Edited by Jie Jack Li.
© 2025 John Wiley & Sons, Inc. Published 2025 by John Wiley & Sons, Inc.
1
276
https://t.me/med1917
Chemistry and Pharmacology of Drug Discovery
1. Background
Migraine headache is commonly characterized by recurrent headaches lasting 4–72 h
with moderate to severe, pulsating pain. Associated symptoms may include nausea and/or
vomiting, and increased sensitivity to light and sound (photophobia and phonophobia,
respectively).
Although it is not a life-threatening disease, due to the severity of the headache, its long
duration, and high prevalence, migraine is a very disabling disorder, which has long
become a significant public health issue in both sexes and all age groups, especially
young and middle-aged women. According to the Global Burden of Disease Study, from
1990 to 2019 (the latest one), migraine remained second
disability (both sexes, all ages) for 30 years, but topped the list in young women in the
global burden disease of 2019.
disability (YLDs) globally, accounting for 4.76% of all YLDs caused by 396
with
diseases.
availability of migraine-specific drugs, nonsteroidal anti-inflammatory drugs (NSAIDs)
such as, aspirin, acetaminophen, ibuprofen, and naproxen were used to treat mild
migraine pain, but do not work in the majority of migraine patients.
efforts accumulated in this area, the pathophysiology of migraine started to reveal itself,
but contention remains, especially around the initiation of migraine. There are two
dominant hypotheses about the mechanism behind migraine: the vascularly focused
hypothesis and the neuroanatomically focused hypothesis (Figure
2
The influence of migraine is often underestimated by non-migraineurs.
among the world’s causes of
3
Migraine was responsible for 41.1 million years lived
4
In the past, without understanding of the mechanism behind migraine and
1
Since research
1).
Figure 1. Overview of migraine-specific medications and their possible
targets. Source: de Vries et al.
The vascularly focused hypothesis centered around the perivascular CGRPergic
transmission of the trigemino-vascular system, which proposed a three-step model of
migraine initiation: (1) release of several neuropeptides including CGRP from the
5
/with permission of Elsevier
277
https://t.me/med1917
Chapter 1 . Rimegepant (Nurtec ODT)
3
perivascular trigeminal nerve branches; (2) induction of vasodilation by CGRP; (3)
Activation of nociceptors on the trigeminal nerve by vasodilation, which is eventually
followed by pain perception.6 This hypothesis supports the use of 5-HT
namely triptans for acute treatment of migraine. It is believed that 5-HT
1B/1D
agonists,
1B/1D
triptans elicit
their antimigraine action by vasoconstriction of excessively dilated intracranial,
extracerebral arteries and/or inhibiting the release of inflammatory neuropeptides from
7
perivascular trigeminal sensory neurons.
8
However, because 5HT receptors are universally expressed in many organs and
drugs.
Triptans 4–10 are now all available as generic
tissues, one of the major concerns with triptans is their potential adverse effect on the
cardiovascular system, which led to restricted use of triptans in patients with
cardiovascular diseases. It has been suggested that 5-HT
vasoconstriction, while inhibition of neuropeptide release is mediated via the 5-HT
receptor activation results in
1B
1D
receptor. However, a randomized clinical trial of the 5-HT1D selective agonist PNU-
9
142633 failed to demonstrate significant efficacy over placebo.
5-HT1F receptor has
become the next target, which is also believed to inhibit pre-junctional release of CGRP
in the trigeminal ganglion and does not play a role in vasoconstriction. One brainpenetrant 5-HT1F receptor agonist, Lasmiditan has been approved by the FDA for the
5
acute treatment of migraine with improved cardiovascular safety.
Соседние файлы в папке Библиотека им академика М.И. Перельмана